Already a big seller, Boehringer Ingelheim GmbH's Jardiance looks set to become a mega-blockbuster as the diabetes drug's expansion into heart failure, and very probably kidney disease, brings in millions more patients and millions more euros.
Boehringer Pharma Chief Confident Of Continued Success For Jardiance
SGLT2 Inhibitor Set For Further Expansion
Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.
More from Strategy
• By
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
More from Business
• By
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.